BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 18, 2024
Product Development

Tumor cell surface targets off the beaten path

Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors
BioCentury | Jun 8, 2023
Discovery & Translation

Modalities, not targets, drive translational innovation at ASCO23

BioCentury’s analysis of first-in-human studies at ASCO 2023
BioCentury | May 18, 2023
Regulation

May 18 Quick Takes: Vaccines panel backs Pfizer RSV vaccine

Plus: Pressure mounts on CMS over Alzheimer’s therapies, financing updates for Coherent, Myeloid, Cabaletta, RedCloud, CytoCares, and more   
BioCentury | Feb 29, 2016
Clinical News

SOR-C13: Phase I data

BioCentury | Jan 18, 2016
Clinical News

SOR-C13: Completed Phase I enrollment

BioCentury | Aug 20, 2012
Clinical News

SOR-C13: Phase I started

BioCentury | Jul 23, 2012
Company News

Soricimed, Mount Allison University deal

Items per page:
1 - 7 of 7